title: Cytomegalovirus-induced Hemorrhagic Colitis in a Patient with Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront Therapy.
abstract: Dasatinib is a kinase inhibitor indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase and accelerated (myeloid or lymphoid blast) phase, and CML with resistance or intolerance to prior therapy including imatinib and in adults with Ph+ acute lymphoblastic leukemia1 The most common adverse reactions (≥15%) in patients with newly diagnosed chronic-phase (CP) CML include myelosuppression, fluid retention, and diarrhea, whereas in patients with resistance or intolerance to prior imatinib therapy, side effects include myelosuppression, fluid retention, diarrhea, headache, dyspnea, skin rash, fatigue, nausea, and hemorrhage. We report a 39-year-old Ethiopian female patient who received dasatinib as upfront therapy for the treatment of CP-CML who experienced chronic diarrhea for two months, which progressed to hemorrhagic colitis due to cytomegalovirus (CMV) infection of the colon. To our knowledge, this is the first case of CMV colitis in a patient receiving dasatinib as upfront therapy.
authors.affiliation: National Center for Cancer Care and Research, Department of Hematology and BMT, Hamad Medical Corporation, Doha, Qatar.
authors.forename: Mohamed A
authors.initials: MA
authors.lastname: Yassin
authors.affiliation: National Center for Cancer Care and Research, Department of Nursing, Hamad Medical Corporation, Doha, Qatar.
authors.forename: Abdulqadir J
authors.initials: AJ
authors.lastname: Nashwan
authors.affiliation: Department of Pediatrics, University of Alexandria, Doha, Qatar.
authors.forename: Ashraf T
authors.initials: AT
authors.lastname: Soliman
authors.affiliation: National Center for Cancer Care and Research, Department of Hematology and BMT, Hamad Medical Corporation, Doha, Qatar.
authors.forename: Anil
authors.initials: A
authors.lastname: Yousif
authors.affiliation: National Center for Cancer Care and Research, Department of Hematology and BMT, Hamad Medical Corporation, Doha, Qatar.
authors.forename: Afra
authors.initials: A
authors.lastname: Moustafa
authors.affiliation: National Center for Cancer Care and Research, Department of Hematology and BMT, Hamad Medical Corporation, Doha, Qatar.
authors.forename: Afaf
authors.initials: A
authors.lastname: AlBattah
authors.affiliation: National Center for Cancer Care and Research, Department of Hematology and BMT, Hamad Medical Corporation, Doha, Qatar.
authors.forename: Shehab F
authors.initials: SF
authors.lastname: Mohamed
authors.affiliation: National Center for Cancer Care and Research, Department of Hematology and BMT, Hamad Medical Corporation, Doha, Qatar.
authors.forename: Deena S
authors.initials: DS
authors.lastname: Mudawi
authors.affiliation: National Center for Cancer Care and Research, Department of Hematology and BMT, Hamad Medical Corporation, Doha, Qatar.
authors.forename: Sarah
authors.initials: S
authors.lastname: Elkourashy
authors.affiliation: National Center for Cancer Care and Research, Department of Nursing, Hamad Medical Corporation, Doha, Qatar.
authors.forename: Deena-Raiza
authors.initials: DR
authors.lastname: Asaari
authors.affiliation: National Center for Cancer Care and Research, Department of Nursing, Hamad Medical Corporation, Doha, Qatar.
authors.forename: Hope-Love G
authors.initials: HL
authors.lastname: Gutierrez
authors.affiliation: National Center for Cancer Care and Research, Department of Pharmacy, Hamad Medical Corporation, Doha, Qatar.
authors.forename: Mohamed
authors.initials: M
authors.lastname: Almusharaf
authors.affiliation: National Center for Cancer Care and Research, Department of Pharmacy, Hamad Medical Corporation, Doha, Qatar.
authors.forename: Radwa M
authors.initials: RM
authors.lastname: Hussein
authors.affiliation: Department of Radiology, Hamad Medical Corporation, Doha, Qatar.
authors.forename: Abbas H
authors.initials: AH
authors.lastname: Moustafa
authors.affiliation: National Center for Cancer Care and Research, Department of Hematology and BMT, Hamad Medical Corporation, Doha, Qatar. ; Department of Radiology, Heart Hospital, Hamad Medical Corporation, Doha, Qatar.
authors.forename: Hatim El
authors.initials: HE
authors.lastname: Derhoubi
authors.affiliation: National Center for Cancer Care and Research, Department of Hematology and BMT, Hamad Medical Corporation, Doha, Qatar.
authors.forename: Sarra
authors.initials: S
authors.lastname: Boukhris
authors.affiliation: Department of Pathology, AlAzhar University, Doha, Qatar.
authors.forename: Samah
authors.initials: S
authors.lastname: Kohla
authors.affiliation: Qatar Medical Genetic Center, Hamad Medical Corporation, Doha, Qatar.
authors.forename: Nader
authors.initials: N
authors.lastname: AlDewik
keywords: CML; colitis; dasatinib